Snakebite envenoming
Conditions
Interventions
COVIP Plus vaccine
Placebo
Sponsors
Africa Centre of Excellence in Phytomedicine Research and Development University of Jos
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All adults 18 years and above that volunteer for the study and grant consent will be recruited into the study
Exclusion criteria
Exclusion criteria: 1. Pregnant women 2. Very old persons (>75 years). 3. Highly malnourished adults (BMI <18.5). 4. Those with a history or Family history of intolerance to Mucuna Pruriens seed. 5. Those detected to be suffering from renal and hepatic disease through the examination of the laboratory tests profile. 6. Those undergoing treatment for immunodeficiency and immunosuppressive disorders such as HIV/AIDS and Cancer. 7. Those on immunosuppressive medication such as steroids, radiotherapy and anticancer medications. 8. Women of childbearing age will be screened for pregnancy and will be counseled to avoid pregnancy in the first month of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety profile of the vaccine;Efficacy and immunogenicity profile of the vaccine;Documentation of the appropriate dosing and schedule for the vaccine | — |
Secondary
| Measure | Time frame |
|---|---|
| A profile of antibodies against common snakebites in the environment;The documentation of the comparative efficacy of COVIP-Plus induced sera against commonly commercial available sera;Documentation of safety profile of COVIP-Plus vaccine on selected haematological and biochemical parameters in human | — |
Countries
Nigeria
Contacts
Public ContactUchechukwu Ohaeri
Data Manager
Outcome results
None listed